Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL)
U
Utpal Dave, MD
Primary Investigator
Administratively Closed
18 years - 100 years
All
Phase
N/A
2 Locations
Brief description of study
The purpose of this study is to test the safety and efficacy of combining two drugs, ixazomib and romidepsin. It will also measure the percentage of patients whose tumor completely resolves after receiving ixazomib and romidepsin.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Peripheral T-cell Lymphoma (PTCL)
-
Age: 18 years - 100 years
-
Gender: All
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
- 18 years or older
- Histological confirmation of peripheral T-cell lymphoma (PTCL)
For a full list of participation criteria, please visit clinicaltrials.gov.
Updated on
25 Mar 2025.
Study ID: 1901200042 (BTCRC-HEM15-028)
